About
Technology
Issues
FAQ
Links
Official Page
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.